$149.52
0.75% yesterday
Nasdaq, Oct 15, 10:05 pm CET

Repligen Corporation Stock price

$149.52
+35.78 31.46% 1M
+22.90 18.09% 6M
+5.58 3.88% YTD
+4.54 3.13% 1Y
-55.13 26.94% 3Y
-20.49 12.05% 5Y
+122.05 444.30% 10Y
+146.24 4,458.54% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+1.12 0.75%

Key metrics

Basic
Market capitalization
$8.4b
Enterprise Value
$8.2b
Net debt
positive
Cash
$708.9m
Shares outstanding
56.3m
Valuation (TTM | estimate)
P/E
negative | 87.2
P/S
12.5 | 11.4
EV/Sales
12.2 | 11.1
EV/FCF
77.7
P/B
4.1
Financial Health
Equity Ratio
69.7%
Return on Equity
-1.3%
ROCE
0.9%
ROIC
1.2%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$674.0m | $740.8m
EBITDA
$125.9m | $146.7m
EBIT
$25.1m | $100.4m
Net Income
$-13.8m | $96.5m
Free Cash Flow
$106.0m
Growth (TTM | estimate)
Revenue
-11.4% | 16.8%
EBITDA
98.6% | 48.8%
EBIT
451.2% | 732.3%
Net Income
-462.0% | 478.2%
Free Cash Flow
-11.2%
Margin (TTM | estimate)
Gross
51.0%
EBITDA
18.7% | 19.8%
EBIT
3.7%
Net
-2.1% | 13.0%
Free Cash Flow
15.7%
More
EPS
$-0.3
FCF per Share
$1.9
Short interest
8.2%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Repligen Corporation forecast:

21x Buy
78%
6x Hold
22%

Analyst Opinions

27 Analysts have issued a Repligen Corporation forecast:

Buy
78%
Hold
22%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
674 674
11% 11%
100%
- Direct Costs 330 330
20% 20%
49%
344 344
1% 1%
51%
- Selling and Administrative Expenses 276 276
8% 8%
41%
- Research and Development Expense 47 47
11% 11%
7%
126 126
99% 99%
19%
- Depreciation and Amortization 101 101
43% 43%
15%
EBIT (Operating Income) EBIT 25 25
451% 451%
4%
Net Profit -14 -14
462% 462%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Neutral
GlobeNewsWire
about 21 hours ago
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET
Neutral
Seeking Alpha
21 days ago
Repligen Corporation (NASDAQ:RGEN ) Bank of America Global Healthcare Conference 2025 September 25, 2025 6:35 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks, everyone, for j...
Neutral
Seeking Alpha
about one month ago
Repligen Corporation (NASDAQ:RGEN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good morn...
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,778
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today